ProfileGDS5678 / 1456034_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 61% 61% 61% 60% 61% 64% 63% 61% 61% 60% 61% 60% 61% 62% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.6691761
GSM967853U87-EV human glioblastoma xenograft - Control 23.6354861
GSM967854U87-EV human glioblastoma xenograft - Control 33.6364861
GSM967855U87-EV human glioblastoma xenograft - Control 43.5393660
GSM967856U87-EV human glioblastoma xenograft - Control 53.592661
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.8678264
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.8655963
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.6271161
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.6280261
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.5998460
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.6282661
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.5671960
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.6434961
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.7071162